c-610

N/A

Report date: 2023/10/20 20:06:50

Base Information

Drug Namec-610

Drug Alias NamePeripheral blood mononuclear cells (PBMCs)-c610PD-1 positive T cells therapyc610c-610

ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Lentiviral vectorCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapyCell and gene therapy > Cell therapy > Source of cells > PMBC-derived

Mechanisms of ActionT lymphocyte replacements

TargetsNot applicable

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesTumor Research Institute Chinese Academy Of Medical Sciences

China Registration ClassN/A

Develop Information

Active CompaniesCancer Hospital Of Chinese Academy Of Medical Sciences

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A